Tempus AI

Tempus AI Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Tempus AI (TEM) as of Nov 5, 2026 is 89.01 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 26.78 % — a change of 232.31% (higher).

Cash Conversion

89.01 %

YoY

232.31%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Tempus AI is 2025 89.01 % . Cash Conversion Rate (OCF/Net Income) of Tempus AI was 2024 26.78 % . It decreases by 232.31% higher compared to the previous year.

The Tempus AI Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
101.88 USD
Jan 1, 2020
98.43 USD
Jan 1, 2021
81.79 USD
Jan 1, 2022
58.04 USD
Jan 1, 2023
100.10 USD
Jan 1, 2024
26.78 USD
Jan 1, 2025
89.01 USD
The Tempus AI Cash Conversion history
YEARCash ConversionYoY
89.01 %+232.31%
26.78 %-73.24%
100.10 %+72.48%
58.04 %-29.04%
81.79 %-16.91%
98.43 %-3.38%
101.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Cash Conversion Rate (OCF/Net Income) of Tempus AI is 89.01 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Tempus AI changed from 26.78 % to 89.01 %, representing a 232.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Tempus AI with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tempus AI

All Key Metrics — Tempus AI